Classification and Epidemiology

Recurrent aphthous stomatitis (RAS) affects 15-25% of the general population with recurrence intervals ranging from 1-2 times yearly to multiple ulcers monthly. Female predominance is 2-3:1, with peak onset typically in adolescence (13-20 years). Approximately 33% of patients report significant impact on quality of life, including pain-associated dietary restrictions and functional impairment.

Ulcers are classified by size and severity:

Minor Aphthous Ulcers (80-90% of RAS cases):
  • Diameter: 2-5mm
  • Depth: involves epithelium and superficial lamina propria
  • Location: buccal mucosa (80%), lips, floor of mouth, soft palate
  • Duration: 7-14 days (89% healed by day 14, >99% by day 21)
  • Scarring: rare (<1%)
  • Pain severity: moderate (typically 3-5/10 pain scale)
Major Aphthous Ulcers (10-15% of cases):
  • Diameter: >5mm (may exceed 1cm)
  • Depth: extends to deep lamina propria or submucosa
  • Location: soft palate, anterior tonsillar pillar, lips
  • Duration: 2-8 weeks (mean 3-4 weeks)
  • Scarring: common (70-80%), permanent if >1cm diameter
  • Pain severity: severe (typically 6-9/10 pain scale)
Herpetiform Ulcers (5-10% of cases):
  • Presentation: 10-100 tiny pinpoint ulcers clustered together
  • Diameter: <1mm each
  • Duration: 7-14 days
  • May coalesce into larger ulcers (2-3mm) as condition progresses
  • Differential diagnosis consideration: Herpes simplex virus (HSV-1) infection, which presents similarly but includes antecedent vesicular stage and higher systemic symptoms

Etiology and Pathophysiology

RAS is fundamentally an oral mucosal immune disorder characterized by abnormal T-cell mediated response to oral epithelial antigens. Biopsy of active ulcers demonstrates dense CD8+ T-cell infiltration surrounding necrotic epithelium, distinct from viral infections where polymorphonuclear leukocytes predominate.

Triggering Factors (present in 60-80% of RAS patients): Trauma: Mechanical injury from orthodontic appliances, sharp foods, or accidental cheek biting during eating precipitates 30-40% of ulcers. Injury may be microscopic (clinically inapparent), explaining ulcer onset without recalled trauma. Nutritional Deficiencies: Iron, folate, or vitamin B12 deficiency present in 5-10% of RAS patients. Laboratory evaluation indicated if:
  • Ulcers appearing monthly or more frequently (>6/year)
  • Major aphthous pattern
  • Associated systemic symptoms (fatigue, pallor, paresthesias)
Deficiency prevalence increases in vegetarian/vegan populations (B12), malabsorption disorders (all three), and menstruating women (iron, especially with heavy flows). Food Triggers: 40-60% of RAS patients report specific food associations:
  • Acidic fruits (citrus, pineapple, tomato): Direct epithelial irritation
  • Sodium lauryl sulfate (SLS) in toothpaste: Mucin layer depletion reducing protective barrier
  • Sodium benzoate, canola oil, cinnamon: Sensitization reactions (rare)
  • Aphthogenic foods high in arginine: Herpes simplex reactivation theory (evidence controversial)
Emotional Stress: 40-50% of patients report ulcer clusters during or shortly after psychological stress. Mechanism likely immune dysregulation from stress hormone effects on regulatory T-cell function. Systemic Conditions: Important etiologic associations warrant investigation if RAS is new-onset, severe, or progressive:
  • Behรงet's disease (presenting symptom in 60-65% of cases)
  • HIV infection with CD4 <200 cells/ฮผL (ulcerations occur in 30-50%)
  • Celiac disease and gluten sensitivity (5-20% higher RAS prevalence)
  • Inflammatory bowel disease (Crohn's disease, ulcerative colitis): associated in 5-8%
  • Periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome: pediatric, recurrent clusters
  • Immunodeficiency syndromes

Diagnostic Assessment

History should establish:

  • Frequency of ulceration (monthly? weekly?)
  • Pattern (isolated ulcers vs. clustered?)
  • Associated symptoms (vesicles preceding ulceration? systemic symptoms?)
  • Triggering factors noted by patient
  • Response to prior treatments
  • Impact on function and quality of life
  • Associated systemic symptoms (fever, arthritis, genital ulcers, ocular symptoms)
Clinical examination documents:
  • Morphology (size, depth, whether ulcer bed is clean yellow-fibrin covered or infected)
  • Location (anterior minor ulcers? posterior major ulcers suggestive of more severe pathology?)
  • Extent of disease (single ulcer? multiple scattered? clustered herpetiform?)
  • Surrounding tissue response (erythema, edema)
  • Associated findings (other oral lesions, gingivitis, tongue changes?)
Investigations:

Routine laboratory evaluation indicated if:

  • Ulcer frequency >6 per year
  • Major aphthous pattern present
  • Age >35 years at first occurrence (suggests systemic etiology)
  • Associated systemic symptoms

Testing should include:
  • Complete blood count (iron-deficiency anemia, immunodeficiency patterns)
  • Iron studies (ferritin, transferrin saturation): if anemia or family history
  • Serum B12 and folate levels
  • Tissue transglutaminase (tTG) antibodies: celiac screening
  • Comprehensive metabolic panel: baseline renal/hepatic function if systemic treatment considered
HSV-1 serology may be helpful if clinical presentation suggests herpetiform variant; PCR from ulcer swab provides definitive diagnosis in 48 hours if suspicion high.

Biopsy is rarely indicated for typical RAS, but should be considered if:

  • Clinical presentation atypical (vegetative border, undermined edges, central necrosis)
  • Ulcer persists >4 weeks without healing
  • Patient age >50 with new-onset oral ulceration (oral cancer concern)
  • Associated constitutional symptoms

Treatment Strategies

Topical Corticosteroids (First-Line):

Potency determines efficacy:

  • Low potency (hydrocortisone 1%): minimal efficacy, 5-15% healing acceleration
  • Medium potency (triamcinolone 0.1%): moderate efficacy, 25-35% healing acceleration
  • High potency (flucinonide 0.05%, clobetasol 0.05%): maximal efficacy, 40-50% healing acceleration

Application method affects bioavailability. Direct ulcer application (post-meal) permits 15-30 minutes contact before food/saliva washout. Application frequency: 3-4 times daily optimal; 2-3 times daily acceptable.

Clinical response: Topical steroids reduce pain by 60-80% within 24-48 hours but minimally accelerate ulcer closure (mean reduction 2-3 days in 7-10 day course). Repeated application prevents secondary ulcer formation in some patients.

Safety: Short-term topical steroid use (<3 weeks, <5mg/day hydrocortisone equivalent) has minimal systemic absorption (<2% bioavailable); candidiasis risk is low but increases with duration >3 weeks or concurrent high-dose systemic steroids.

Topical Antimicrobials:

Secondary bacterial infection occurs in 10-20% of aphthous ulcers, particularly major ulcers or those in high-plaque regions. Clinical signs of infection include:

  • Increased surrounding erythema and edema
  • Purulent exudate
  • Systemic symptoms (fever, lymphadenopathy)

Treatment: Chlorhexidine 0.12% rinses or triclosan paste reduces infection-associated swelling and accelerates secondary closure by 2-3 days. Topical Anesthetics:

Topical anesthetics (benzocaine 20%, lidocaine 2%) provide rapid pain relief lasting 15-30 minutes, enabling normal eating. Overuse may mask expanding infection or more serious pathology; prudent use limits application to 3-4 times daily.

Systemic Corticosteroids (Severe/Major Ulcers):

Indicated for:

  • Major aphthous ulcers with severe pain limiting oral function
  • Clusters of multiple major ulcers
  • RAS interfering with nutrition or quality of life despite topical therapy

Dosing: Prednisone 40-60 mg daily for 3-5 days, then taper. Clinical response includes 30-40% pain reduction within 48 hours and 25-35% acceleration of healing (reducing typical 3-4 week course to 2-3 weeks).

Adverse effects from short course: minimal (insomnia, mild appetite stimulation). Risk-benefit ratio favors treatment in major ulcers causing significant morbidity.

Systemic Therapies (Recurrent/Severe RAS):

For patients with >6 ulcers annually or major ulcers monthly, systemic therapy consideration:

Colchicine (antimicrotubule agent): 0.5-1.0 mg daily reduces ulcer frequency by 40-60%, duration by 30-40%. Mechanism unclear; may involve immune-modulation or epithelial renewal acceleration. Thalidomide (immunomodulatory): 50-200 mg daily dramatically reduces RAS frequency (80-90% improvement) and heals major ulcers within 1-2 weeks. However, severe teratogenicity risk limits use to specialized centers under strict REMS (Risk Evaluation and Mitigation Strategy) protocols. Pentoxifylline (rheologic agent): 400 mg three times daily shows modest benefit (30-40% frequency reduction). Generally well-tolerated with minimal adverse effects. Interferon-alpha (cytokine): Intralesional injection shows promise but impractical for routine use.

Prevention Strategies

Trauma Avoidance:
  • Orthodontic wax application to sharp bracket edges reduces RAS incidence by 30-40% in bracketed patients
  • Careful chewing technique (slow, deliberate)
  • Avoid foods with sharp edges (chips, hard candies, nuts)
Oral Hygiene Modification:
  • Switch toothpaste to sodium lauryl sulfate (SLS)-free formulation: 65-70% of SLS-sensitive patients show frequency reduction
  • Soft-bristled toothbrush with gentle technique
  • Daily chlorhexidine 0.12% rinses: preventive effect in frequent recurrence (>6/year) showing 30-40% ulcer reduction
Dietary Modification:
  • Identify and eliminate specific food triggers
  • Avoid extremely hot foods/beverages (mechanical irritation)
  • Consider elimination diet (2-4 weeks avoiding common triggers) to identify patterns
Nutritional Supplementation:
  • Iron supplementation if iron-deficient (ferritin <30 ng/mL): 325 mg ferrous sulfate daily reduces RAS frequency by 60-70% over 12 weeks in deficient patients
  • Vitamin B12 supplementation if deficient (B12 <200 pg/mL): 1,000 mcg monthly injections or sublingual 2,000 mcg daily
  • Folate supplementation if deficient: 1-5 mg daily
  • Zinc supplementation: 25-50 mg daily if deficient (consider in celiac disease, malabsorption states)
Systemic Evaluation:
  • Celiac serology if unexplained RAS or associated abdominal symptoms
  • HIV testing if major/atypical ulcers, immunocompromised appearance, or behavioral risk factors
  • Behรงet's disease evaluation if genital ulcers, ocular symptoms, or arthritis present

Conclusion

Recurrent aphthous ulcers affect 15-25% of the population with variable severity. Minor ulcers (80-90% of cases) heal spontaneously in 7-14 days and benefit from topical corticosteroid therapy reducing pain by 60-80%. Major ulcers require systemic corticosteroids to prevent scarring and accelerate healing. Frequent recurrence (>6/year) warrants nutritional assessment and systemic evaluation for celiac disease, HIV, or Behรงet's disease. Prevention through trauma avoidance, SLS-free toothpaste, dietary modification, and nutritional supplementation (if deficient) reduces ulcer frequency by 30-70%. Patients should seek professional evaluation if ulcers persist >3 weeks, worsen despite treatment, or are associated with systemic symptoms.